Hyderabad: Pharma Player Natco Pharma on Monday said it has reported a 40 per cent rise in consolidated net profit for the fourth quarter ended March 31, 2024 to Rs 386 crore as against Rs 276 crore in the same quarter last year. corresponding quarter of the previous financial year (Q4FY23).

This was a growth of nearly 20 per cent in consolidated Q4FY24 revenue at Rs 1110 crore compared to Rs 927 crore in Q4FY23.

However, for FY 2023-24 the company reported its highest ever consolidated net profit of Rs 1388 crore, up 94 per cent from FY 23 net profit of Rs 715 crore. It had a record consolidated total revenue of Rs 4127 crore for FY 24, up 47 per cent from Rs 2812 crore recorded in FY 23.

The company said that domestic trade On this front, the company took a one-time charge of about Rs 90 crore, which was reflected in revenue and expenses. Profitability Numbers,

In Pharma Formulations In the domestic business, the company said it returned and accounted for stock worth about Rs 35 crore from super-stockists to C&F. Business Model,

In Crop Health Sciences (CHS) business, stock returns were higher than expected by Rs 25 crore due to poor crop season and provisions on assets stood at Rs 1,00,000 crore. CHS Divisions The amount was around Rs 30 crore. “This was done due to non-utilisation of some of the assets that were used for mining. Manufacture of agricultural intermediatesThe company told the stock markets.